Generelt er slike aksjer risikable og da snakker jeg også av egen erfaring. Men skulle de lykkes er det stort potensiale for dette selskapet og eierne. Selvsagt er det den mulige oppside som er attraktiv i slike selskap. Mener Circio Holding kan inneha nok kvaliteter/ressurser til å lykkes. Her er det positive nyheter som gjelder i hvert fall i første omgang. Selvsagt er økonomien viktig, men den vil bedres betydelig hvis de skulle lykkes med noen av deres studier.

Beklager men ingen har troen på dette selskapet lenger. Troen på Julenissen har større oppslutning enn dette selskapet CRNA eller Targovax som det het tidligere.
Ledelsen trodde kanskje at et navneskifte skulle hjelpe?

Spennende ting på gang, er det om de overlever og kan fortsette festen med å grafse til seg penger fra aksjonærene?

Selskapet børsmelder i dag.
· ONCOS-102 combined with chemotherapy demonstrated 34.1% overall survival (OS)
rate at 30 months in first line patients, compared to 0% in the chemotherapy
-only group
· ONCOS-102 promoted robust immune responses, including an association between
T-cell infiltration and patient survival

Bør være av interesse for aksjonærer og investorer.

Og dermed spratt aksjen opp 14,3%.

Noen fagfolk her inne som kan fortelle nærmere hva dagens melding innebærer. Var dette et gjennombrudd? Veien videre.

· ONCOS-102 combined with chemotherapy demonstrated 34.1% overall survival (OS)
rate at 30 months in first line patients, compared to 0% in the chemotherapy
-only group
· ONCOS-102 promoted robust immune responses, including an association between
T-cell infiltration and patient survival

Oslo, Norway, 4 September 2023- Circio Holding ASA (OSE: CRNA), a biotechnology
company developing novel circular RNA and immunotherapy medicines, today
announces that the completed phase 1/2 trial of ONCOS-102 in combination with
Standard of Care (SoC) chemotherapy in malignant pleural mesothelioma (MPM) has
been published in the Journal for ImmunoTherapy of Cancer (JITC), the
prestigious immunology journal of the Society for Immunotherapy of Cancer
(SITC).

The study was a randomized phase 1/2 trial adding ONCOS-102 to SoC chemotherapy
(pemetrexed/cisplatin) in first and later line MPM to assess safety, immune
activation and clinical efficacy in a total of 31 patients. The ONCOS-102 and
SoC combination showed a favorable safety profile, robust immune responses in
injected tumors and a signal of clinical benefit. In first line patients, the OS
rate at 30 months was 34.1% for ONCOS-102-treated patients, which is a clear
improvement over the first-line SoC-only control group where the OS rate was 0%.

Title of publication: ONCOS-102 plus pemetrexed and platinum chemotherapy in
malignant pleural mesothelioma: a randomized phase 2 study investigating
clinical outcomes and the tumor microenvironment

For the full publication, please see link:
https://jitc.bmj.com/content/11/9/e007552

Margrethe Sørgaard, VP and Head of Clinical at Circio, said: "Mesothelioma
remains a challenging disease with poor prognosis and few available treatment
options. In this exploratory trial, ONCOS-102 demonstrated a clear signal of
clinical benefit for this underserved patient group, particularly in an early
treatment setting. Importantly, the study also showed that ONCOS-102 can be
safely and effectively combined with chemotherapy and drive robust immune
activation in an immunologically cold tumor type, thereby demonstrating the
versatility of the product and expanding future development opportunities."

***

For further information, please contact: Legger ut hele meldingen som aqksjonærene fikk i går. Til orientering for interesserte.

Dette var gode nyheter. Ut med Kinamann og inn med et stort seriøst selskap. God lesning : https://news.cision.com/circio/r/circio-announces-in-vivo-proof-of-concept-for-its-circvec-circular-rna-platform-technology-and-reinf,c3962653

Gode nyheter??? Kaller ikke dette gode nyheter. Lykke til med henting av penger. Tror mange har brent sine fingre i dette tapssluket og de få som har vært med hele veien, har et vanvittig papirtap.

Noen som vet når man oppdaterer dette i markedet. Skal det bli en emisjon så er det vel viktig at alle er like informert som en eventuelt en investor er det.

TOP 50 bare øker og øker sist nå med 71 300 aksjer
Oversikt for CIRCA (CIRCA GROUP AS ). Oppdatert VPS 24.05.2024

01 NORSKE SKOG ASA 25.92% 35.61m 31.65m
02 SAXO BANK A/S 14.75% 20.26m 18.01m
03 CITIBANK, N.A. 11.74% 16.13m 14.34m
04 CIRCA GROUP AS 5.30% 7 280.3k 6 471k
05 DUNCAN ANTHONY JAMES 4.49% 6 165k 5 480k
06 LAWRENCE CHRISTOPHER HOWARD 3.31% 4 547.4k 4 042k
07 NORDNET LIVSFORSIKRING AS 2.21% 3 038k 2 700k 469
08 J.P. MORGAN SE 1.80% 2 475k 2 200k
09 TEAM AMERICA PTY LTD 1.45% 1 995k 1 773k
10 MOATA PTY LTD 0.98% 1 350k 1 200k
11 PERSHING LLC 0.87% 1 191.8k 1 059k
12 BMS INVEST AS 0.82% 1 125.2k 1 000k
13 LEIN ANDREAS LUDVIGSEN 0.52% 718.93k 639k ++++++36 000
14 INTERACTIVE BROKERS LLC 0.52% 709.25k 630.4k
15 HELLERUD TOR 0.49% 678.77k 603.4k
16 NORDNET BANK AB 0.44% 606.29k 538.9k -14 725
17 SKANDINAVISKA ENSKILDA BANKEN AB 0.41% 562.5k 500k
18 SKIHUS AS 0.34% 469.39k 417.2k
19 TRIVON AS 0.33% 450k 400k
20 HØGNABBEN AS 0.31% 426.38k 379k
21 MORTEN CARLSON AS 0.30% 417.18k 370.8k
22 JOHNSEN HARALD MORTEN 0.30% 410.63k 365k
23 M PAULEN HOLDING AS 0.30% 408.04k 362.7k
24 HALDEN THORLEIF 0.29% 393.75k 350k ++++++++++50 000
25 GILBO ODD AUGUST 0.28% 381.07k 338.7k
26 KLAVENESS MARINE FINANCE AS 0.27% 364.06k 323.6k
27 JØRSTAD JAN-HENRIK 0.25% 346.52k 308k
28 WINGE JØRGEN 0.25% 337.97k 300.4k
29 NORDEA BANK ABP 0.25% 337.84k 300.3k
30 THIRTY EIGHTH SEPELDA P/L ATF FINC 0.25% 337.5k 300k
31 RISA FORVALTNING AS 0.23% 315k 280k
32 PROFECTUS-INVEST AS 0.22% 308.89k 274.6k
33 LAM CONG LUONG 0.22% 303.75k 270k
34 KOLBEINSHAVN HELGE 0.21% 292.5k 260k
35 SPERRE LARS PEDER SØRVAAG 0.21% 285.25k 253.6k
36 GRINDVOLL IDAR ANDERSEN 0.21% 284.52k 252.9k
37 HERSETH AS 0.19% 258.75k 230k
38 MIDDELBOE AS 0.19% 258.75k 230k
39 TEIEN OLE ANDREAS 0.19% 256.33k 227.8k
40 HØSE AS 0.17% 238.44k 212k
41 JANSSON KRISTIAN HENRY 0.17% 234.28k 208.3k
42 SWEDBANK AB 0.17% 227.7k 202.4k
43 SIX SIS AG 0.17% 226.7k 201.5k
44 TANGERUD KJETIL KEITH 0.16% 225.52k 200.5k
45 LBM INVEST AS 0.16% 225k 200k
46 REINERTSEN INGE 0.16% 225k 200k
47 T.M.C INVEST AS 0.16% 225k 200k
48 CARLSON MORTEN ALF 0.15% 210.6k 187.2k
49 BRAATHEN JØRGEN HELLUM 0.15% 208.17k 185k
50 AAS GAUTE 0.15% 206.39k 183.5k
51 Other investors 16.62% 22.83m 20.29m -71 300